Speed AVF Maturation for Dialysis Patients
Dialysis is a life-saving treatment for patients with end-stage renal disease. Creation of arteriovenous (AV) fistulas are often the best option for permanent vascular access in these patients. Once mature, AV fistulas allow a conduit for regular dialysis, however, failure rates remain high (reaching up to 70%) due to lack of fistula maturation; often requiring secondary surgeries or percutaneous interventions to promote clinical usability.
Up to 70% of AVFs Fail due to lack of maturation.
Alucent aims to improve AV fistula maturation by adding its NVS technology to the AVF procedure – with a particular focus on improving outcomes in the most challenging patients, those with veins with sub optimal diameters.
Pre-Clinical signals demonstrate NVS can potentially promote vein remodeling thus speeding & enhancing the physiological and functional maturation of the AVF – helping patients more rapidly and reliably have regular life-saving dialysis.
Based on histological evidence in pre-clinical research, a hybrid fistula creation including the NVS therapy can reduce potential of injury to the vein due to sudden changes in blood flow and facilitate rapid fistula maturation leading to more successful outcomes.